Kimmie Ng
Associate Professor of Medicine, Harvard Medical School
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (24)
Year:
2026
Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection
Year:
2025
Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus
Year:
2025
Table S5. Hazard ratio of cancer-specific mortality by plasma 25-hydroxyvitamin D levels in plasma biomarker companion study and by predicted vitamin D scores in diet and lifestyle companion study
Year:
2025
Figure S2. Dose-response relationship and test of linearity for the hazard ratio (HR) of disease-free survival (A), overall survival (B), and time to recurrence (C) by continuous predicted vitamin D scores, with reference of plasma 25-hydroxyvitamin D set at 12 ng/ml
Year:
2025
Background The incidence of early-onset (EO) gastrointestinal (GI) cancers—commonly defined as being diagnosed in patients <50 years of age—is rising at an alarming rate globally. The rising incidence demonstrates a birth cohort effect, implicating environmental factors, such as diet and lifestyle; however, the drivers behind this trend are not yet known. Methods A comprehensive narrative review of the literature was conducted, focusing on EO colorectal, oesophagogastric, and pancreatic cancers. Additionally, the literature on less common EO GI cancers, including appendiceal, biliary, and neuroendocrine tumours, was reviewed. Epidemiological trends, risk factors, clinical and molecular characteristics, germline and somatic genetic features, and outcomes across these diseases were examined. Results EO GI cancers have demonstrated a consistent rise in incidence, which disproportionally affects black, Hispanic, and indigenous populations and women. Though germline pathogenic variants are more common in EO GI cancers compared with average-onset GI cancers, most cases occur sporadically. Modifiable risk factors associated with an increased risk of EO GI cancers include obesity, a Western-pattern diet, non-alcoholic fatty liver disease, smoking, and alcohol use, among others. Across GI cancers, younger patients frequently present with more aggressive disease features and receive more intensive treatment compared with older patients. Survival outcomes are inconsistent across studies. Conclusion EO GI cancers represent clinically distinct disease entities that are associated with unique challenges in screening, management, and survivorship. A better understanding of underlying aetiologies, optimized screening strategies, and improved survivorship support are necessary. Meeting the needs of this growing patient population will require a multidisciplinary, equity-based approach in both clinical care and research.
Year:
2025
Ovarian cancers and microsatellite stable (MSS) colorectal cancers are insensitive to anti–programmed cell death 1 (PD-1) immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggest a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase I dose escalation study of pembrolizumab and the angiopoietin 1/2 inhibitor trebananib (NCT03239145). This multicenter trial enrolled patients with metastatic ovarian cancer or MSS colorectal cancer. Trebananib was administered intravenously weekly for 12 weeks with 200 mg intravenous pembrolizumab every 3 weeks. The toxicity profile of this combination was manageable, and the protocol-defined highest dose level (trebananib 30 mg/kg weekly plus pembrolizumab 200 mg every 3 weeks) was declared the maximum tolerated dose. The objective response rate for all patients was 7.3% (90% confidence interval, 2.5%–15.9%). Three patients with MSS colorectal cancer had durable responses for ≥3 years. One responding patient’s colorectal cancer harbored a POLE mutation. The other two responding patients had left-sided colorectal cancers, with no baseline liver metastases, and genomic analysis revealed that they both had KRAS wild-type, ERBB2 -amplified tumors. After development of acquired resistance, biopsy of one patient’s KRAS wild-type ERBB2 -amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD-1 immunotherapy combinations.
Year:
2025
Current treatments for KRAS -mutant colorectal cancers are often limited by cellular plasticity and rewiring responses. Here we describe a promising therapeutic strategy that simultaneously targets epigenetic and oncogenic signals. Specifically, we show that inhibitors of histone methyltransferase, EZH2, synergize with various rat sarcoma virus (RAS) pathway inhibitors and promote dramatic tumor regression in vivo . Together these agents cooperatively suppress Wingless and Int-1 (WNT)-driven transcription and drive colorectal cancers into a more differentiated cell state by inducing the Groucho/transducin-like enhancer corepressor, TLE4 , along with a network of WNT pathway inhibitors and intestinal differentiation proteins. However, these agents also induce the proapoptotic protein BCL2 modifying factor (BMF), which subsequently kills these more differentiated cells. Accordingly, cell death can be prevented by activating β-catenin, by blocking differentiation, or by ablating BMF expression. Collectively, these studies reveal a new therapeutic approach for treating KRAS- mutant colorectal cancers and illustrate a critical convergence of EZH2 and RAS on oncogenic WNT signals, intestinal differentiation, and apoptosis. Significance: Combined EZH2 and RAS pathway inhibitors kill KRAS- mutant colorectal cancer cells and promote durable tumor regression in vivo . These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.
Year:
2024
Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus
Year:
2024
Purpose: To assess whether higher plasma 25-hydroxyvitamin D (25[OH]D) are associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Patients and Methods: Plasma samples were collected from 1437 patients with stage III colon cancer enrolled in a phase III randomized clinical trial (CALGB/SWOG 80702) from 2010 to 2015, who were followed until 2020. Cox regressions were used to examine associations between plasma 25(OH)D and disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Mediation analysis was performed for circulating inflammatory biomarkers of CRP, IL-6, and sTNF-R2. Results: Vitamin D deficiency (25(OH)D
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (37)
Juha Väyrynen
University of Oulu
Hersh Gupta
Dana-Farber Cancer Institute
Sandro Santagata
Brigham and Women's Hospital
Annacarolina da Silva
Assistant Professor of Pathology and Laboratory Medicine
Weill Cornell Medical College
En Cheng
Assistant Professor
Albert Einstein College of Medicine
Livio Trusolino
Full Professor, University of Torino School of Medicine
Candiolo Cancer Institute, FPO-IRCCS
Aladdin Shadyab
Associate Professor
University of California, San Diego
Pushpamali De Silva
Dana-Farber Cancer Institute
Emma Welsh
Dana-Farber Cancer Institute
Eileen M. O'Reilly
Attending
Memorial Sloan Kettering Cancer Center
Fred Tabung
University of South Carolina
Qian Shi
Mayo Clinic
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Kristian Helin
CEO, Professor
Institute of Cancer Research
Qiao-Li Wang
Affliated Researcher
Lund University
Karen Cichowski
Professor
Brigham and Women's Hospital
Andrew D Cherniack
Group Leader
Dana-Farber Cancer Institute
Jeffrey Clark
Associate Professor
Harvard University
Srivatsan Raghavan
Assistant Professor
Dana-Farber Cancer Institute
Bruno Bockorny
Beth Israel Deaconess Medical Center
Scott Rodig
Professor of Pathology
Beth Israel Deaconess Medical Center
Andrea Bertotti
Candiolo Cancer Institute
Peter Sorger
Otto Krayer Professor of Systems Pharmacology
Harvard Medical School
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
JoAnn Manson
Professor
Harvard Medical School
Elizabeth Cohen
Dana-Farber Cancer Institute
Naiara Perurena
Group Leader
Instituto de Investigación Sanitaria Aragón
Steven Corsello
Stanford University
Sheheryar Kabraji
Associate Professor
Roswell Park Comprehensive Cancer Center
Owen J. Sansom
Director
Cancer Research UK Beatson Institute
Thuy Mai Van Nguyen
Imperial College London
juhua luo
Professor
Indiana University Bloomington School of Public Health
Chen Yuan
Assistant Professor
Cedars-Sinai Medical Center
Priya Kumthekar
Northwestern Medicine
Michael Rosenthal
Brigham and Women's Hospital
Matthew Meyerson
Director, Center for Cancer Genomics
Dana-Farber Cancer Institute
Nazmus Saquib
-
Make your next move.
Prepare your application
Review drafts before you send them.